Clinical trial · Interventional
Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer
Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Using scintigraphy to plan specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the side effects and best way to give intensity-modulated radiation therapy and to see how well it works in treating patients with stage I, stage II, stage III, or stage IV prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| goserelin acetate | Drug | Goserelin | ALIAS |
| image-guided radiation therapy | Radiation | — | UNRESOLVED |
| intensity-modulated radiation therapy | Radiation | — | UNRESOLVED |
| leuprolide acetate | Drug | Leuprolide | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- Toxicity
- measure
- Survival rates
- measure
- Freedom from biochemical relapse rates
- measure
- Local control rates
- measure
- Distant failure rates
- measure
- Biochemical freedom from failure rates
- measure
- Comparison of outcomes to patients treated with conventional radiotherapy and intensity-modulated radiotherapy without radioimmunoguidance
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 19 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Pathologically confirmed prostate cancer * Stage I-IV disease (T1-4, N0-1, M0) * No evidence of distant metastases (M0) on physical examination or bone scan PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Hemoglobin ≥ 10.0 g/dL * WBC ≥ 3,000/mcL * Platelet count ≥ 90,000/mm * AST \< 2 times the upper limit of normal * No allergy to leuprolide acetate or goserelin PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available